Patent US3065414A successfully refreshed from Google Patents.
US4479931A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for non-invasive detection of ocular melanoma
Assignee: United States Department of Energy
•
Filing: 1982-09-23
•
Granted: 1984-10-30
•
Expires: 2002-09-23
Abstract
Abstract There is described an apparatus and method for diagnosing ocular cancer that is both non-invasive and accurate which comprises two radiation detectors positioned before each of the patient's eyes which will measure the radiation level produced in each eye after the administration of a tumor-localizing radiopharmaceutical such as gallium-67.
Inventors
- 👤 Richard M. Lambrecht
- 👤 Samuel Packer
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 12:24
CPC Classifications
A; A61; A61B; A61B3/00; A61B3/10; A61B6/00; A61B6/42; A61B6/4208; A61B6/4258; G; G01; G01T; G01T1/00; G01T1/16; G01T1/161
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
98 words
A method for non-invasively and accurately diagnosing ocular cancer comprising: (a) providing two radiation detectors; (b) positioning each of said detectors respectively before each of the eyes of a subject so that each detector will measure the radiation level in its associated eye under substantially identical conditions; (c) simultaneously measuring and recording the integrated output of each of said detectors, thereby to normalize said measured radiation levels to a preselected standard, whereby a predetermined positive differential recorded for the normalized radiation level of one detector gives an indication of ocular cancer in the eye associated with that detector.
Claim 2
Independent Claim
98 words
A method for non-invasively and accurately diagnosing ocular cancer comprising: (a) providing two radiation detectors; (b) positioning each of said detectors respectively before each of the eyes of a subject so that each detector will measure the radiation level in its associated eye under substantially identical conditions; (c) simultaneously measuring and recording the integrated output of each of said detectors, thereby to normalize said measured radiation levels to a preselected standard, whereby a predetermined positive differential recorded for the normalized radiation level of one detector gives an indication of ocular cancer in the eye associated with that detector.
Claim 3
Dependent Claim
28 words
A method as described in claim 1, wherein said detector is collimated so as to substantially reduce its exposure to radiation from sources other than the associated eye.
Claim 4
Dependent Claim
19 words
A method as described in claim 2, further comprising providing a standard radiation source for periodically calibrating said detectors.
Claim 5
Dependent Claim
23 words
A method as described in claim 1, wherein said detectors are chosen to be responsive to radiation from a pre-selected tumor localizing radiopharmaceutical.
Claim 6
Dependent Claim
22 words
A method as described in claim 4, wherein said radiopharmaceutical is chosen from a group consisting of gallium-67, iodine-123, iodine-125 and fluorine-18.
Claim 7
Dependent Claim
20 words
A method as described in claim 1, wherein said radiopharmaceutical is gallium-67 citrate and said detectors are sodium iodide detectors.
Claim 8
Independent Claim
91 words
A method for detecting ocular cancer comprising the steps of: (a) administering a tumor localizing radiopharmaceutical to a subject; (b) simultaneously separately measuring the level of radioactivity in each eye of said subject; (c) comparing the levels so measured by normalizing each of the measured levels relative to a preselected standard level and by measuring the differential between the normalized levels relating to the respective eyes, whereby a predetermined positive differential in one of the normalized measured levels gives an indication of ocular cancer in the eye showing the positive differential.
Claim 9
Independent Claim
91 words
A method for detecting ocular cancer comprising the steps of: (a) administering a tumor localizing radiopharmaceutical to a subject; (b) simultaneously separately measuring the level of radioactivity in each eye of said subject; (c) comparing the levels so measured by normalizing each of the measured levels relative to a preselected standard level and by measuring the differential between the normalized levels relating to the respective eyes, whereby a predetermined positive differential in one of the normalized measured levels gives an indication of ocular cancer in the eye showing the positive differential.
Claim 10
Dependent Claim
22 words
A method as described in claim 7, wherein said radiopharmaceutical is chosen from a group consisting of gallium-67, iodine-123, iodine-125 and fluorine-18.
Claim 11
Dependent Claim
13 words
A method as described in claim 8, wherein said radiopharmaceutical is gallium-67 citrate.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-10-30 | 1988-04-30 | 1988-10-30 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-10-30 | 1992-04-30 | 1992-10-30 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-10-30 | 1996-04-30 | 1996-10-30 | $7700.00 | Window Closed / Lapsed |